thalidomide has been researched along with Brain Injuries in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quelling microglial-induced excessive neuroinflammation is a potential treatment strategy across neurological disorders, including traumatic brain injury (TBI), and can be achieved by thalidomide-like drugs albeit this approved drug class is compromised by potential teratogenicity." | 8.31 | Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. ( Baig, AM; Chiang, YH; Greig, NH; Hoffer, BJ; Hsueh, SC; Hwang, I; Kim, DS; Kim, S; Kim, YK; Lecca, D; Luo, W; Tweedie, D; Vargesson, N, 2023) |
| "Quelling microglial-induced excessive neuroinflammation is a potential treatment strategy across neurological disorders, including traumatic brain injury (TBI), and can be achieved by thalidomide-like drugs albeit this approved drug class is compromised by potential teratogenicity." | 4.31 | Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. ( Baig, AM; Chiang, YH; Greig, NH; Hoffer, BJ; Hsueh, SC; Hwang, I; Kim, DS; Kim, S; Kim, YK; Lecca, D; Luo, W; Tweedie, D; Vargesson, N, 2023) |
| "Present knowledge of chromosomal aberrations associated with microphthalmia is surveyed, and some of the syndromes and phenocopies in the mentally retarded in which microphthalmia may be found are reviewed." | 2.35 | The heterogeneity of microphthalmia in the mentally retarded. ( Warburg, M, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, J | 1 |
| Jiang, J | 1 |
| He, B | 1 |
| Lin, WJ | 1 |
| Li, Y | 1 |
| Duan, J | 1 |
| Li, H | 1 |
| Huang, X | 1 |
| Cai, J | 1 |
| Xie, J | 1 |
| Zhang, Z | 1 |
| Yang, Y | 1 |
| Xu, Y | 1 |
| Hu, X | 1 |
| Wu, M | 1 |
| Zhuo, X | 1 |
| Liu, Q | 1 |
| Shi, Z | 1 |
| Yu, P | 1 |
| Rong, X | 1 |
| Ye, X | 1 |
| Saw, PE | 1 |
| Wu, LJ | 1 |
| Simone, CB | 1 |
| Chua, MLK | 1 |
| Mai, HQ | 1 |
| Tang, Y | 1 |
| Lecca, D | 2 |
| Hsueh, SC | 1 |
| Luo, W | 4 |
| Tweedie, D | 4 |
| Kim, DS | 2 |
| Baig, AM | 1 |
| Vargesson, N | 1 |
| Kim, YK | 1 |
| Hwang, I | 1 |
| Kim, S | 1 |
| Hoffer, BJ | 4 |
| Chiang, YH | 1 |
| Greig, NH | 4 |
| Lin, CT | 1 |
| Yang, LY | 1 |
| Scerba, MT | 1 |
| Huang, PS | 1 |
| Jung, YJ | 1 |
| Yang, CH | 1 |
| Wang, JY | 2 |
| Baratz, R | 2 |
| Rubovitch, V | 2 |
| Pick, CG | 2 |
| Yoon, JS | 1 |
| Warburg, M | 1 |
1 review available for thalidomide and Brain Injuries
| Article | Year |
|---|---|
The heterogeneity of microphthalmia in the mentally retarded.
Topics: Abnormalities, Multiple; Abortifacient Agents; Adolescent; Adult; Brain Injuries; Child, Preschool; | 1971 |
1 trial available for thalidomide and Brain Injuries
| Article | Year |
|---|---|
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury.
Topics: Animals; Bevacizumab; Blood-Brain Barrier; Brain; Brain Injuries; Mice; Radiation Injuries; Thalidom | 2023 |
4 other studies available for thalidomide and Brain Injuries
| Article | Year |
|---|---|
Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury.
Topics: Animals; Brain Injuries; Brain Injuries, Traumatic; Chick Embryo; Humans; Immunomodulating Agents; I | 2023 |
3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation.
Topics: Animals; Brain Injuries; Cytokines; Encephalitis; Male; Mice; Mice, Inbred C57BL; Microglia; Neurons | 2020 |
Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice.
Topics: Animals; Apoptosis; Brain; Brain Injuries; Cognition Disorders; Disease Models, Animal; Enzyme-Linke | 2015 |
Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice.
Topics: Animals; Avoidance Learning; Behavior, Animal; Brain Chemistry; Brain Injuries; Cell Line; Inflammat | 2011 |